In 2016, cancer biologist Johanna Joyce of the Memorial Sloan Kettering Cancer Center published a study in Science that examined the effects of a macrophage-targeted therapy on glioblastoma multiforme ...

A new Oncoscience perspective maps the 2025–2026 glioblastoma clinical trial pipeline across four mechanistic domains, ...

Preliminary clinical data for glioblastoma multiforme patients enrolled in a Phase 1 clinical trial demonstrated that 92 percent of evaluable patients treated with INB-200 exceeded a median ...

Glioblastoma multiforme (GBM), or simply glioblastoma, is a highly aggressive type of cancer that starts in your brain or spinal cord. It tends to spread quickly, and people with GBM often have poor ...

A new research perspective was published in Volume 13 of Oncoscience on September 17, 2026, titled "Emerging pharmacological agents for glioblastoma multiforme: An update on active clinical trials ...

Human cytomegalovirus (hCMV) is part of the Herpesviridae family. It infects nearly half of the French population. Once infected, individuals are generally lifelong carriers of the virus, as is the ...

Gleolan, a dye used for brain imaging, can help surgeons visualize tumor tissue during surgery for glioblastoma multiforme. Malignant transformation occurs from aggregation of genetic alterations and ...